Darolutamide submitted for EU approval
Orion Corporation and Bayer have submitted a marketing application in Europe for use of darolutamide in patients with a certain type of prostate cancer.
Read More
Tag: Orion Corporation
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
